Results 21 to 30 of about 5,391,353 (307)

Antibody Engineering

Microbiology Spectrum, 2014
ABSTRACTAdvanced molecular biology techniques developed during the past few decades have allowed the industry to exploit and commercialize the natural defense mechanisms that antibodies provide. This review discusses the latest advances in antibody-engineering technologies to enhance clinical efficacy and outcomes.
Kin-Ming, Lo, Olivier, Leger, Björn, Hock   +2 more
openaire   +2 more sources

Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice

Viruses, 2020
The genus Henipavirus (HNVs) includes two fatal viruses, namely Nipah virus (NiV) and Hendra virus (HeV). Since 1994, NiV and HeV have been endemic to the Asia–Pacific region and responsible for more than 600 cases of infections. Two emerging HNVs, Ghana
Yaohui Li, Ruihua Li, Meirong Wang, Yujiao Liu, Ying Yin, Xiaodong Zai, Xiaohong Song, Yi Chen, Junjie Xu, Wei Chen   +9 more
doaj   +1 more source

A novel built-in adjuvant metallothionein-3 aids protein antigens to induce rapid, robust, and durable immune responses

Frontiers in Immunology, 2022
Adjuvants are crucial components of vaccines that can enhance and modulate antigen-specific immune responses. Herein, we reported for the first time that human metallothionein-3 (MT3), a low molecular weight cysteine-rich metal-binding protein, was a ...
Ying Yin, Yanfei Gu, Xiaodong Zai, Ruihua Li, Xinjie Zhu, Rui Yu, Jun Zhang, Shuyi Wang, Yue Zhang, Jian Lin, Junjie Xu, Wei Chen   +11 more
doaj   +1 more source

Antibody Engineering at the Millennium [PDF]

BioTechniques, 2000
It has been almost 100 years since von Behring and Kitasato received the first Nobel prize for the discovery of passive immunotherapy and nearly 25 years since Köhler and Milstein first reported hybridoma technology. In the 15 years since Mullis and co-workers described PCR, a number of discoveries and technologies have converged to produce a ...
Jorge V. Gavilondo, James W. Larrick
openaire   +3 more sources

Engineering of the binding profile of a new class of antibody like proteins

, 2022
reservedAfter a manual screening of antibody like protein candidates obtained from computational analysis, the most ranked candidate has been selected for engineering the binding-surface against a specific molecular ...
CARTURA, MATTEO
core  

A novel one-step approach for the construction of yeast surface display Fab antibody libraries

Microbial Cell Factories, 2018
Background Yeast surface display (YSD) has proven to be a versatile platform technology for antibody discovery. However, the construction of antibody Fab libraries typically is a tedious three-step process that involves the generation of heavy chain as ...
Simon Rosowski, Stefan Becker, Lars Toleikis, Bernhard Valldorf, Julius Grzeschik, Deniz Demir, Iris Willenbücher, Ramona Gaa, Harald Kolmar, Stefan Zielonka, Simon Krah   +10 more
doaj   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies

mAbs
Multidrug resistance (MDR) hinders efficacious cancer chemotherapy. Overexpression of the P-glycoprotein (P-gp) efflux pump (EP) on cancer cells is a primary cause of MDR since it expels numerous anticancer drugs.
Raffaella Briante, Qianting Zhai, Suchismita Mohanty, Pingping Zhang, Alissa O’Connor, Hiwot Misker, Willie Wang, Cindy Tan, Mastewal Abuhay, Jessica Morgan, Richard Theolis, Paul Ponath, Robert Arathoon   +12 more
doaj   +1 more source

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Journal of Immunology Research, 2019
To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library.
Weiyi Qiu, Chang Zhang, Shuang Wang, Xiaoyan Yu, Qiong Wang, Dadi Zeng, Peng Du, Jinling Ma, Yiqiong Zheng, Bo Pang, Yunzhou Yu, Feng Long, Xiaobin Pang, Zhiwei Sun   +13 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

ipRGCs Sensitive Blue Light Exposure Promotes the Robustness of Circadian and Neural Stem Cells in Sleep Deprived Conditions

Stem Cells International
Circadian rhythm abnormalities due to sleep deprivation (SD) may promote the development of emotional and cognitive disorders. Though light therapies have been employed to treat circadian disorders, the exact treatments and their underlying biology are ...
Zhaoting Bu, Xiaotong Li, Jinyu Shi, Qiaozhen Qin, Heyang Zhang, Yuanrong Qiu, Lingyu Zhang, Yifei Tan, Hanping Shi, Xiaoxia Jiang   +9 more
doaj   +1 more source